March 25th 2024
Developed by the AUGS Scientific Committee and Research Agenda Writing Group
February 23rd 2024
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Once-daily quinolone effective for uncomplicated UTI
January 1st 2003San Diego-A new once-daily formulation of ciprofloxacin (Cipro XR) is equivalent to conventional twice-daily dosing for treatment of uncomplicated urinary tract infections, according to results from a large, multicenter randomized trial. The extended-release formulation was granted FDA approval last month.
Philly, Northeast Pa reeling from practice closings
December 1st 2002Philadelphia-The City of Brotherly Love has what many say is theleast friendly climate for physicians when it comes to medical liabilityinsurance. Insurance and reimbursement problems, however, are statewidephenomena in Pennsylvania. In Scranton, located in the northeastern cornerof the state, a seven-urologist group has said it will decide in Januarywhether to close.
Novel proteomics test detects 95% of prostate cancers
December 1st 2002Bethesda, MD-A screening technique based on the interplay of blood proteinsmay help clearly differentiate between prostate cancer and benign conditionslike BPH, according to a National Cancer Institute study. The test, whichis still under investigation, showed a specificity of 71% in men with marginallyelevated PSA levels, NCI researchers reported.
Materials, techniques for SUI continue to evolve
December 1st 2002New minimally invasive techniques for the surgical treatment of stressincontinence have been based on novel concepts concerning the surgical supportof the mid-urethra and the utilization of artificial graft materials. Inthis exclusive Urology Times interview, David Staskin, MD, discusses theevolution of sling techniques and the pros and cons of using artificialmaterials. Dr. Staskin is director of the Section of Voiding Dysfunction,New York Presbyterian Hospital, and associate professor of urology and obstetricsand gynecology, Weill Medical College, Cornell University. The interviewwas conducted by UT Editorial Consultant Philip M. Hanno, MD, of the departmentof urology, University of Pennsylvania, Philadelphia.
Newer markers may improve on PSA's shortcomings
October 1st 2002Q What is the current state of prostate cancer markers?With prostate cancer, we are fortunate in that it has the very best markeror combination of markers for any cancer that I'm aware of, short of skincancer where visual markers are quite good. PSA's performance for predictinglocalized prostate cancer probably exceeds the performance of other cancermarkers, such as CA125 for ovarian cancer, CEA for colon cancer, and someof the genetic markers for breast cancer.
Bone density scores need to be revised for men
September 1st 2002Orlando, FL-Currently established T- and Z- bone mineral density scores may require revision in order to accurately assess changes in men receiving androgen deprivation therapy, suggests an Austrian study presented at the AUA annual meeting.
How to successfully manage neonatal hydronephrosis
July 1st 2002The incidence of hydronephrosis diagnosed in the neonatal period has increased dramatically with the routine use of ultrasound in obstetrical care. Prior to the mid-1980s, most children with obstructive uropathy secondary to ureteropelvic junction obstruction or ureterovesical junction obstruction were diagnosed after urinary tract infections had occurred or an abdominal mass was noted.
Targeted therapies inhibit PCa bone metastasis
June 1st 2002San Francisco-Prostate cancer bone metastases appear to react favorablyto treatment with a new bisphosphonate and the tyrosine-kinase inhibitorsPKI-166 and STI-571, according to studies presented at the American Associationfor Cancer Research annual meeting here.
Advances in anticholinergic therapy delivery systems
June 1st 2002Characterized by symptoms of urinary frequency, urgency, and urge urinary incontinence, overactive bladder (OAB) is a condition that results from a deficiency in the bladder's ability to store urine and in the onset of involuntary bladder muscle contractions that promote urgency and possibly urine loss.
Coalition pushes for prostate cancer research funding
May 1st 2002Group presses for $420 million at NIH and $100 million at Defense Departmentin 2003Washington - The case for bolstering funding for prostate cancerresearch is being pressed on Capitol Hill by a 6-year-old coalition of organizationsand individuals who are determined to end the disease that has accountedfor 15% of all male cancer deaths over the last decade.
Endocrine disruptors may explain hypospadias increase
April 1st 2002San Francisco - Researchers have successfully induced hypospadias in mice, an accomplishment that observers say provides more compelling evidence in support of the endocrine disruptor hypothesis as an explanation for the increase in hypospadias observed over the past 30 years.
Prediction of future infertility can come even earlier
April 1st 2002San Francisco-Factors that may help to predict future infertilityin cryptorchid boys-enabling clinicians to intervene earlier-have emergedfrom two long-term studies of cryptorchidism and fertility presented atthe American Academy of Pediatrics Section on Urology annual meeting.
Studies support continued role for varicocelectomy
February 1st 2002Varicocele was first recognized by Lawrence Dubin, MD, and Richard D.Amelar, MD, as the male reproductive anatomic anomaly most amenable to surgicalcorrection. Varicocelectomy has long since played an important role in theurologist's toolbox. Yet with the emergence of intracytoplasmic sperm injection, a variantof in vitro fertilization in which a single sperm is injected into an ovum,some have questioned the utility of all forms of reproductive therapy otherthan assisted reproductive technologies (ARTs). Among many papers presentedat the American Society for Reproductive Medicine annual meeting-and reportedin this issue of Urology Times-several supported the continued role forvaricocelectomy.
Varicocelectomy found more cost effective than ART
February 1st 2002Orlando, FL-Is assisted reproduction technology (ART) a better way to deal with varicocele-related infertility, or is surgical repair the better choice? Given the high pregnancy success of ART, the optimal management of infertility secondary to varicocele is unclear," said Paul J. Turek, MD, associate professor of urology, University of California, San Francisco.
Botulinum shows promise for added urologic indications
February 1st 2002Jena, Germany-Botulinum toxin has shown promise as a potential therapy for chronic pelvic pain and lower urinary tract dysfunction. In a German study, injection of botulinum toxin type A into the urethral sphincter muscle led to improvement in muscle tone, pain, and urodynamic parameters in patients enrolled.
High risk of testicular Ca found in infertile men
February 1st 2002Orlando, FL-Infertile men are at increased risk for testicular cancer compared with the general population. That is the disturbing conclusion reached by researchers at the New York Weill-Cornell Medical Center, following a study of 4,470 men over a 13-year period.